Federal health advisers recommended government approval of the first inhaled form of insulin, offering some diabetics an alternative to many of their daily injections.
Panel members twice voted 7-2 to recommend FDA approval of Exubera for each of the two most common types of diabetes.
Drug company representatives proposed to conduct studies on the long-term effects of the drug until 2019.
“We understand the need to assess the long-term effects on pulmonary function,” said Dr. Neville Jackson of Pfizer.
Read our original Exubera story